High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy

Cancer

Volumn 110, Issue 1, 2007, Pages 156-163

  Ridola, Vita ^a   Grill, Jacques ^a   Doz, Francois ^b   Gentet, Jean Claude ^c   Frappaz, Didier ^d   Raquin, Marie Anne ^a   Habrand, Jean Louis ^a   Sainte Rose, Christian ^e   Valteau Couanet, Dominique ^a   Kalifa, Chantal ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c TIMONE HOSPITAL   (France)

^d CENTRE LÉON BÉRARD   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Busulfan; Intellectual outcome; Primitive neuroectodermal tumors; Recurrence; Salvage therapy; Thiotepa

Indexed keywords

BUSULFAN; CARBOPLATIN; CLONAZEPAM; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; THIOTEPA; URSODEOXYCHOLIC ACID;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW APLASIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DEATH; DRUG MEGADOSE; HUMAN; INFECTION; LIVER VEIN OBSTRUCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG ASPERGILLOSIS; MEDULLOBLASTOMA; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; POSTERIOR FOSSA; PRIORITY JOURNAL; RADIATION DOSE; SEPTICEMIA; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPERGILLOSIS; BUSULFAN; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT; LUNG DISEASES, FUNGAL; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PNEUMONIA; RADIOTHERAPY, CONFORMAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THIOTEPA; TREATMENT OUTCOME;

EID: 34250811390     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22761     Document Type: Article

References (36)

1. Kuhl J, Doz F, Taylor RE. Embryonic tumors. In: Walker DA, Perilongo G, Punt JAG, Taylor RE, eds. Brain and Spinal Tumors of Childhood. London: Arnold Publisher; 2004:314-330.
2. Mulhern RK, Palmer SL, Reddick WE, et al. Risk of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol. 2001;19:472-479.
3. Suc E, Kalifa C, Brauner R, et al. Brain tumors under the age of three. The price of survival. Acta Neurochir. 1990;106:93-98.
4. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol. 2001;19:2302-2308.
5. Grill J, Viguier D, Kieffer V, et al. Critical risk factors for intellectual impairment in children with posterior fossa tumors: the role of cerebellar damage. J Neurosurg. 2004;101:152-158.
6. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;17:1725-1731.
7. Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol. 1994;12:1607-1615.
8. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-7631.
9. Gajjar A, Mulhern RK, Heideman RL, et al. Medulloblastoma in very young children: outcome of definitive craniospinal irradiation following incomplete response to chemotherapy. J Clin Oncol. 1994;12:1212-1216.
10. Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol. 2005;23:7152-7160.
11. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6:573-580.
12. Kalifa C, Hartmann O, Demeocq F, et al. High dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant. 1992;9:227-233.
13. Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol. 1996;27:87-98.
14. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogenic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:975-981.
15. Gnekow A. Recommendations of the Brain Tumor Subcommittee for the reporting of trials. SIOP Brain Tumor Subcommittee.International Society of Pediatric Oncology. Med Pediatr Oncol. 1995;24:104-108.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events: version 3.0 (CTCAE). Available at URL: http://ctep.cancer.gov/forms/ CTCAEv3.pdf Accessed August 9, 2006.
17. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
18. Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definitions for response and relapse in children with brain tumors. Cancer. 1985;56:1824-1826.
19. Wechsler D. Manual for the Wechsler Preschool and Primary Scale of Intelligence. Revised ed. New York, NY: Psychological Corporation; 1989.
20. Wechsler D. Wechsler Intelligence Scale for Children. 3rd ed. New York, NY: Psychological Corporation; 1991.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-448.
22. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis. 1978;31:557-560.
23. Gentet JC, Doz F, Bouffet E, et al. Carboplatin and VP 16 in medulloblastoma: a phase II study of the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol. 1994;23:422-427.
24. Valteau-Couanet D, Filippini B, Grill J, et al. High dose busulphan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant. 2005;36:939-945.
25. Walter AW, Mulhern RK, Gajjar A, et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol. 1999;17:3720-3728.
26. Bouligand J, Boland I, Valteau-Couanet D, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant. 2003;32:979-986.
27. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84:321-330.
28. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337-4343.
29. Teinturier C, Hartmann O, Valteau-Couanet D, et al. Ovarian function after autologous bone marrow transplantation in childhood: high dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1988;22:989-994.
30. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6:209-218.
31. Poirot C, Brugieres L, Genestie C, Martelli H. Ovarian tissue cryopreservation for prepubertal girls: indications and feasibility. Gynecol Obstet Fertil. 2005;33:799-803.
32. Kieffer-Renaux V, Bulteau C, Grill J, et al. Visual agnosia after treatment of a posterior fossa ependymoma in a 16-month-old girl. J Child Neurol. 2001;16:698-704.
33. Notteghem P, Soler C, Dellatolas G, et al. Neuropsychological outcome in long-term survivors of a childhood extracranial solid tumor who have undergone autologous bone marrow transplantation. Bone Marrow Transplant. 2003;31:599-606.
34. Vassal G, Hartmann O, Habrand JL, Pico JL, Lemerle J. Radiosensitization after busulphan [letter]. Lancet. 1987;1:571.
35. Cairncross G, Swinnen L, Bayer R, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro-oncol. 2000;2:114-119.
36. Fouladi M, Chintagumpala M, Laningham FH, et al. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004;22:4551-4560.